Osborne Partners Capital Management LLC Buys 520 Shares of Pfizer Inc. (NYSE:PFE)

Osborne Partners Capital Management LLC lifted its stake in Pfizer Inc. (NYSE:PFE) by 0.3% during the third quarter, Holdings Channel reports. The fund owned 190,699 shares of the biopharmaceutical company’s stock after acquiring an additional 520 shares during the quarter. Osborne Partners Capital Management LLC’s holdings in Pfizer were worth $5,519,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. BKM Wealth Management LLC boosted its holdings in shares of Pfizer by 97.5% during the 3rd quarter. BKM Wealth Management LLC now owns 11,050 shares of the biopharmaceutical company’s stock worth $320,000 after buying an additional 5,455 shares during the period. Allworth Financial LP increased its stake in shares of Pfizer by 4.4% in the third quarter. Allworth Financial LP now owns 117,755 shares of the biopharmaceutical company’s stock worth $3,408,000 after purchasing an additional 4,915 shares during the period. Mayfair Advisory Group LLC boosted its stake in Pfizer by 30.7% during the 3rd quarter. Mayfair Advisory Group LLC now owns 10,279 shares of the biopharmaceutical company’s stock valued at $294,000 after purchasing an additional 2,414 shares during the period. Signet Investment Advisory Group Inc. increased its position in Pfizer by 2.2% in the 3rd quarter. Signet Investment Advisory Group Inc. now owns 119,034 shares of the biopharmaceutical company’s stock worth $3,445,000 after buying an additional 2,507 shares during the period. Finally, Cromwell Holdings LLC lifted its holdings in shares of Pfizer by 16,151.1% during the third quarter. Cromwell Holdings LLC now owns 7,638 shares of the biopharmaceutical company’s stock worth $221,000 after buying an additional 7,591 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Down 0.7 %

Shares of PFE opened at $28.45 on Friday. The firm has a market capitalization of $161.22 billion, a price-to-earnings ratio of -61.87, a PEG ratio of 1.01 and a beta of 0.67. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $31.54. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. The business’s fifty day moving average price is $29.07 and its two-hundred day moving average price is $28.49.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. The firm had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same period last year, the firm earned $0.67 earnings per share. On average, analysts predict that Pfizer Inc. will post 2.67 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be issued a $0.42 dividend. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a yield of 5.91%. Pfizer’s dividend payout ratio is presently -365.21%.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the stock. StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday, October 9th. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and upped their price objective for the company from $28.00 to $34.00 in a research note on Wednesday, August 7th. Sanford C. Bernstein assumed coverage on Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price for the company. Barclays boosted their price target on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Finally, Wells Fargo & Company lifted their price objective on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Eight analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $33.58.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.